1%派立明滴眼液联合0.25%贝特舒混悬液的临床降眼压疗效及安全性观察

目的:观察派立明滴眼液联合贝特舒混悬液对中国人青光眼患者的降眼压疗效及安全性方法:选取原发性开角型青光眼、高眼压症、术后残余青光眼患者共26例44只眼,给予派立明滴眼液及贝特舒混悬液早晚各2次点眼,共观察2个月,分别于用药后2周、4周、6周、8周复查,观察用药前后的眼压及不良反应。结果:派立明联合应用贝特舒每日2次点眼,降眼压效果显著且稳定,眼压平均降低5.03～6.65mmHg(1mmHg=0.133kPa),平均降幅为20.55%～37.30%且不良反应少。结论:派立明滴眼液联合贝特舒混悬液对中国人具有良好的降眼压效果,毒副作用少,可作为临床上青光眼药物治疗的主要用药。

Clinical Investigation:The Intraocular Pressure-lowering Efficacy and Safety of Brinzolamide Combined with Betaxolol

PURPOSE: To evaluate the intraocular pressure (IOP) lowering efficacy and safety of Brinzolamide combined with Betaxolol for the Chinese glaucomatous patients. METHODS: Twenty-six glaucoma patients (44 eyes) diagnosed as primary open angle glaucoma, ocular hypertension and remnant glaucoma (IOP remained high after antiglaucomatous surgeries) were recruited as a research team. After a washing out phase, Brinzolamide 1% combined with Betaxolol 0.25% were administered to them twice daily [(8 +/- 1) o'clock in the morning and (20 +/- 1) o'clock in the evening] respectively. The observing duration was 2 months. The IOP and the side effect before and after the administration of the eyedrops were observed. RESULTS: The average IOP lowering ranged from 5.03 mm Hg to 6.65 mm Hg (1 mm Hg = 0.133 kPa) (20.55% to 37.30%) after the administration of Brinzolamide 1% combined with Betamolol 0.25% twice a day. The IOP lowering effect was stable and the patients complained little uncomfortable. CONCLUSIONS: Brinzolamide combined with Betaxolol has significant IOP lowering effect and few side effect for the Chinese people. Brinzolamide can be used as the main medication for the treatment of glaucoma.